PMA supplement
P050047 S104: Juvéderm Ultra, Juvéderm Ultra XC, and Juvéderm Ultra Plus XC (hereafter referred to as Ultra, Ultra XC and Ultra Plus X
FDA PMA supplement · 30-Day Notice · Allergan
Key facts
| Original PMA | P050047 |
|---|---|
| Supplement number | S104 |
| Supplement type | 30-Day Notice |
| Reason for the supplement | Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| Trade name | Juvéderm Ultra, Juvéderm Ultra XC, and Juvéderm Ultra Plus XC (hereafter referred to as Ultra, Ultra XC and Ultra Plus X |
| Generic name | Implant, dermal, for aesthetic use |
| Applicant | Allergan |
| Product code | LMH |
| Received date | Jun 20, 2025 |
| Decision date | Jul 14, 2025 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: